XML 50 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated statements of changes in equity - EUR (€)
€ in Millions
Total
Attributable to equity holders of Sanofi 
Share capital
Additional paid-in capital
Treasury shares
Reserves and retained earnings
Stock options and other share- based payments
Other comprehensive income
Attributable to non- controlling interests
Beginning balance at Dec. 31, 2019 [1] € 59,230 € 59,056 € 2,508 € 147 € (9) € 51,902 € 3,863 € 645 € 174
Other comprehensive income for the period (4,007) [2] (3,987) [1]       14 [1]   (4,001) [1] (20) [1]
Net income for the period [1] 12,330 12,294       12,294     36
Comprehensive income 8,323 [2] 8,307 [1]       12,308 [1]   (4,001) [1] 16 [1]
Dividend paid out of earnings (3,937) (3,937)       (3,937)      
Payment of dividends to non-controlling interests (44) 0             (44)
Share repurchase program [3] (822) (822)     (822)        
Share-based payment plans:                  
Exercise of stock options [3] 51 51 2 49          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 3 (3) 126 (126)      
Employee share ownership plan [3] 174 174 5 169          
Value of services obtained from employees 274 274         274    
Tax effects of the exercise of stock options 1 1         1    
Other changes arising from issuance of restricted shares [5] 2 2       2      
Ending balance at Dec. 31, 2020 63,252 [6] 63,106 [1] 2,518 [1] 362 [1] (705) [1] 60,149 [1] 4,138 [1] (3,356) [1] 146 [1]
Other comprehensive income for the period 3,307 [2] 3,296       797   2,499 11
Net income for the period 6,279 [2] 6,223       6,223     56
Comprehensive income 9,586 [2] 9,519       7,020   2,499 67
Dividend paid out of earnings (4,008) (4,008)       (4,008)      
Payment of dividends to non-controlling interests (49) 0             (49)
Share repurchase program [3] (382) (382)     (382)        
Share-based payment plans:                  
Exercise of stock options [3] 11 11   11          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 4 (4) 148 (148)      
Employee share ownership plan [3] 168 168 5 163          
Value of services obtained from employees 244 244         244    
Tax effects of the exercise of stock options 23 23         23    
Other changes in non-controlling interests [7] 186 0             186
Ending balance at Dec. 31, 2021 69,031 68,681 2,527 532 (939) 63,013 4,405 (857) 350
Other comprehensive income for the period 2,764 2,759       451   2,308 5
Net income for the period 8,484 8,371       8,371     113
Comprehensive income 11,248 11,130       8,822   2,308 118
Dividend paid out of earnings (4,168) (4,168)       (4,168)      
Effect of the distribution of an exceptional supplementary dividend of 58% of the shares of EUROAPI to the equity holders of Sanofi [8] (793) (793)       (793)      
Payment of dividends to non-controlling interests (100) 0             (100)
Share repurchase program [3] (497) (497)     (497)        
Reduction in share capital [3] 0 0 (13) (587) 600        
Share-based payment plans:                  
Exercise of stock options [3] 35 35 1 34          
Issuance of restricted shares and vesting of existing restricted shares [3],[4] 0 0 3 (3) 130 (130)      
Employee share ownership plan [3] 153 153 4 149          
Value of services obtained from employees 245 245         245    
Tax effects of the exercise of stock options 8 8         8    
Other (10) (10)       (10)      
Ending balance at Dec. 31, 2022 € 75,152 € 74,784 € 2,522 € 125 € (706) € 66,734 € 4,658 € 1,451 € 368
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[2] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] See Notes D.15.1., D.15.3., D.15.4. and D.15.5.
[4] This line includes the use of existing shares to fulfill vested rights under restricted share plans.
[5] Issuance of restricted shares to former employees of the European Generics business subsequent to the date of divestment.
[6] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[7] This line includes changes in non-controlling interests arising from divestments and acquisitions.
[8] This amount includes the valuation of the shares distributed as a dividend in kind, at a price of €14.58 per share, as of May 10, 2022 (see note D.1.).